Literature DB >> 11884563

Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.

Milosz Faber1, Rojjanaporn Pulmanausahakul, Suchita S Hodawadekar, Sergei Spitsin, James P McGettigan, Matthias J Schnell, Bernhard Dietzschold.   

Abstract

A recombinant rabies virus (RV) carrying two identical glycoprotein (G) genes (SPBNGA-GA) was constructed and used to determine the effect of RV G overexpression on cell viability and immunity. Immunoprecipitation analysis and flow cytometry showed that tissue culture cells infected with SPBNGA-GA produced, on average, twice as much RV G as cells infected with RV carrying only a single RV G gene (SPBNGA). The overexpression of RV G in SPBNGA-GA-infected NA cells was paralleled by a significant increase in caspase 3 activity followed by a marked decrease in mitochondrial respiration, neither of which was observed in SPBNGA-infected cells. Furthermore, fluorescence staining and confocal microscopy revealed an increased extent of apoptosis and markedly reduced neurofilament and F actin in SPBNGA-GA-infected primary neuron cultures compared with neuronal cells infected with SPBNGA, supporting the concept that RV G or motifs of the RV G gene trigger the apoptosis cascade. Mice immunized with SPBNGA-GA showed substantially higher antibody titers against the RV G and against the nucleoprotein than SPBNGA-immunized mice, suggesting that the speed or extent of apoptosis directly determines the magnitude of the antibody response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11884563      PMCID: PMC136034          DOI: 10.1128/jvi.76.7.3374-3381.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.

Authors:  Y Shi; W Zheng; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus.

Authors:  L A Ball; C R Pringle; B Flanagan; V P Perepelitsa; G W Wertz
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.

Authors:  J P McGettigan; S Sarma; J M Orenstein; R J Pomerantz; M J Schnell
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.

Authors:  H D Foley; J P McGettigan; C A Siler; B Dietzschold; M J Schnell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

Review 5.  Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  2000-10       Impact factor: 7.486

6.  Apoptosis-mediated enhancement of DNA-raised immune responses by mutant caspases.

Authors:  S Sasaki; R R Amara; A E Oran; J M Smith; H L Robinson
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

7.  Genetic engineering of live rabies vaccines.

Authors:  K Morimoto; J P McGettigan; H D Foley; D C Hooper; B Dietzschold; M J Schnell
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

8.  Abortive rabies virus central nervous infection is controlled by T lymphocyte local recruitment and induction of apoptosis.

Authors:  A Galelli; L Baloul; M Lafon
Journal:  J Neurovirol       Date:  2000-10       Impact factor: 2.643

9.  Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.

Authors:  R Pulmanausahakul; M Faber; K Morimoto; S Spitsin; E Weihe; D C Hooper; M J Schnell; B Dietzschold
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Recombinant rabies virus as potential live-viral vaccines for HIV-1.

Authors:  M J Schnell; H D Foley; C A Siler; J P McGettigan; B Dietzschold; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  77 in total

Review 1.  Experimental rabies vaccines for humans.

Authors:  James P McGettigan
Journal:  Expert Rev Vaccines       Date:  2010-10       Impact factor: 5.217

2.  Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation.

Authors:  Lihong Tao; Jinying Ge; Xijun Wang; Hongyue Zhai; Tao Hua; Bolin Zhao; Dongni Kong; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 3.  The role of immune responses in the pathogenesis of rabies.

Authors:  D Craig Hooper
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

4.  Immunogenicity of cytopathic and noncytopathic viral vectors.

Authors:  Gabriela Plesa; Philip M McKenna; Matthias J Schnell; Laurence C Eisenlohr
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Glycoprotein of nonpathogenic rabies viruses is a key determinant of human cell apoptosis.

Authors:  Christophe Préhaud; Stéphanie Lay; Bernhard Dietzschold; Monique Lafon
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.

Authors:  Amy B Papaneri; John G Bernbaum; Joseph E Blaney; Peter B Jahrling; Matthias J Schnell; Reed F Johnson
Journal:  Virus Res       Date:  2014-12-04       Impact factor: 3.303

7.  PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity.

Authors:  Christoph Wirblich; Gene S Tan; Amy Papaneri; Peter J Godlewski; Jan Marc Orenstein; Ronald N Harty; Matthias J Schnell
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Characterization of a single-cycle rabies virus-based vaccine vector.

Authors:  Emily A Gomme; Elizabeth J Faul; Phyllis Flomenberg; James P McGettigan; Matthias J Schnell
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

Review 9.  Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask).

Authors:  Benjamin M Davis; Glenn F Rall; Matthias J Schnell
Journal:  Annu Rev Virol       Date:  2015-06-24       Impact factor: 10.431

10.  Oral vaccination of raccoons (Procyon lotor) with genetically modified rabies virus vaccines.

Authors:  Jesse D Blanton; Joshua Self; Michael Niezgoda; Marie-Luise Faber; Bernhard Dietzschold; Charles Rupprecht
Journal:  Vaccine       Date:  2007-08-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.